156 related articles for article (PubMed ID: 38230848)
1. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
2. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Lee H; Lim TS; Kim SU; Kim HC
Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
[TBL] [Abstract][Full Text] [Related]
3. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim D; Kim YJ; Yoon JH; Han K; Cho EJ
BMC Med; 2023 Jan; 21(1):4. PubMed ID: 36600263
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
6. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
[TBL] [Abstract][Full Text] [Related]
7. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
8. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
[TBL] [Abstract][Full Text] [Related]
9. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
10. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
12. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
14. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
[TBL] [Abstract][Full Text] [Related]
15. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
16. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
17. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
18. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
20. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]